Association of Epirubicin, Etoposide and Cisplatin in Gastric Cancer
作者:
C. Barone,
A. Cassano,
A. Astone,
E. Ricevuto,
T. Fontana,
MR. Noviello,
C. Garufi,
F. Pacelli,
A. Grieco,
期刊:
Oncology
(Karger Available online 1991)
卷期:
Volume 48,
issue 5
页码: 353-355
ISSN:0030-2414
年代: 1991
DOI:10.1159/000226957
出版商: S. Karger AG
关键词: Gastric cancer;Epirubicin;Etoposide;Cisplatin;Chemotherapy
数据来源: Karger
摘要:
Cisplatin-based drug combinations are now currently investigated in an attempt to surpass the results obtainable by 5-FU alone or by 5-FU-containing regimens. We evaluated 29 patients with advanced and measurable gastric adenocarcinoma treated with etoposide, epirubicin and cisplatin. One patient had complete response (3 ± 7%); 9 patients had partial response (31 ± 17%); 5 patients (17±14%) were considered stable (S) and 14 (48 ± 18%) were classified as progressive. The average survival time for the entire group was 11 months with 25% of the patients alive at 24 months. We feel that cisplatin-containing regimens are promising and deserve further investigations. To clearly explore the potential innovative role of these regimens randomized trials versus FAM or 5-FU alone are mandat
点击下载:
PDF
(1266KB)
返 回